Results 41 to 50 of about 114,242,522 (291)

Interaction of Cysteine Conjugates with Human and Rabbit Organic Anion Transporter 1

open access: yesThe Journal of Pharmacology and Experimental Therapeutics, 2003
Organic anion (OA) transport mediates accumulation of the zwitterionic nephrotoxic cysteine S-conjugates S-dichlorovinylcysteine (DCVC) and S-chlorotrifluoroethylcysteine (CTFC) in the rabbit renal proximal tubule (RPT). Although these cysteine conjugates are nephrotoxic to the human RPT, neither the role of OA transport nor the specific OA transport ...
Groves, C. E.   +4 more
openaire   +3 more sources

Acetylation turns leucine into a drug by membrane transporter switching

open access: yesScientific Reports, 2021
Small changes to molecules can have profound effects on their pharmacological activity as exemplified by the addition of the two-carbon acetyl group to make drugs more effective by enhancing their pharmacokinetic or pharmacodynamic properties. N-acetyl-d,
Grant C. Churchill   +7 more
doaj   +1 more source

Developmental changes in multispecific organic anion transporter 1 expression in the rat kidney [PDF]

open access: yesKidney International, 2000
The cDNA of the multispecific organic anion transporter 1 (OAT1) responsible for the tubular secretion of organic anions was recently isolated. In the current study, we investigated the developmental changes in OAT1 expression in the rat kidney.Ontogenic expression of rat OAT1 was investigated by Northern blot, in situ hybridization, Western blot, and ...
N, Nakajima   +8 more
openaire   +2 more sources

Hypouricemic Effects of Ganoderma applanatum in Hyperuricemia Mice through OAT1 and GLUT9

open access: yesFrontiers in Pharmacology, 2018
Ganoderma applanatum (G. applanatum) dispels wind to eliminate dampness and exhibited nephron- and liver-protective effects as noted in Chinese herbal classic literature; it might also affect hyperuricemia. Therefore, we examined the hypouricemia effects
Tianqiao Yong   +10 more
doaj   +1 more source

Apigenin Ameliorates Hyperuricemia and Renal Injury through Regulation of Uric Acid Metabolism and JAK2/STAT3 Signaling Pathway

open access: yesPharmaceuticals, 2022
Hyperuricemia (HUA) is a kind of metabolic disease with high incidence that still needs new countermeasures. Apigenin has uric-lowering and kidney-protective activities, but how apigenin attenuates HUA and renal injury remains largely unexploited.
Tianyuan Liu   +12 more
doaj   +1 more source

Drug Transporter Expression and Activity in Human Hepatoma HuH-7 Cells

open access: yesPharmaceutics, 2016
Human hepatoma cells may represent a valuable alternative to the use of human hepatocytes for studying hepatic drug transporters, which is now a regulatory issue during drug development. In the present work, we have characterized hepatic drug transporter
Elodie Jouan   +4 more
doaj   +1 more source

Biological Distribution after Oral Administration of Radioiodine-Labeled Acetaminophen to Estimate Gastrointestinal Absorption Function via OATPs, OATs, and/or MRPs

open access: yesPharmaceutics, 2023
We evaluated the whole-body distribution of orally-administered radioiodine-125 labeled acetaminophen (125I-AP) to estimate gastrointestinal absorption of anionic drugs.
Kakeru Sato   +10 more
doaj   +1 more source

Urine-to-Blood Partitioning of Per- and Polyfluoroalkyl Substances in Human Biomonitoring: Implications for Environmental Exposure Analysis and Bioaccumulation Assessment

open access: yesMolecules
Per- and polyfluoroalkyl substances (PFAS) are persistent chemicals with substantial bioaccumulation potential, but their distribution between blood and urine in humans remains poorly characterized.
Peiyao Ye   +4 more
doaj   +1 more source

Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOs

open access: yesMolecular Therapy: Nucleic Acids, 2017
Antisense oligonucleotides are metabolized by nucleases and drug interactions with small drug molecules at either the cytochrome P450 (CYP) enzyme or transporter levels have not been observed to date.
Colby S. Shemesh   +13 more
doaj   +1 more source

Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters

open access: yesPharmaceutics, 2021
Remdesivir has been approved for treatment of COVID-19 and shortens the time to recovery in hospitalized patients. Drug transporters removing remdesivir from the circulation may reduce efficacy of treatment by lowering its plasma levels.
Anne T. Nies   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy